BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study (REAL-CRT)

April 20, 2016 updated by: Gianluca Botto
This study was designed to evaluate the potential benefits of treatment with biventricular device in patients with normal systolic function , indication for pacing and impaired atrio-ventricular conduction , by comparing the treatment with dual-chamber device . The REAL -CRT study is designed to test the hypothesis that, in patients with atrioventricular block of I degree and standard pacing indications , biventricular pacing is superior to single stimulation of the right ventricle (RV) with optimized algorithms for minimization of pacing , as assessed by echocardiography an endpoint defined in terms of maintenance over time of left ventricular ejection fraction (LVEF ) and left ventricular end-systolic volume ( LVESV ) .

Study Overview

Detailed Description

Clinical data suggest that biventricular pacing is able to preserve the myocardial performance more effectively than the right ventricular pacing in patients with atrioventricular block and mild systolic dysfunction . In particular, some studies have shown that medical therapy in these patients could be responsible for an increase in the cumulative percentage of chronic pacing over the 40% threshold , the threshold associated with a higher incidence of atrial fibrillation and hospitalization for heart failure and ventricular arrhythmias . In addition , patients with pre-existing left ventricular dysfunction and indication for pacing standards have improved left ventricular systolic function , exercise capacity and quality of life as a result of biventricular pacing as compared with Right ventricular pacing . These results suggest that biventricular pacing is a feasible option for permanent pacing in patients who have normal systolic function of the left ventricle and that this can be altered from the adverse effects of conventional Right ventricular pacing on systolic function of the left ventricle . This reality has prompted physicians to assess the value and role of cardiac resynchronization therapy (CRT ) in patients with prolonged Atrio-Ventricular (AV) conduction . Note the deleterious effects of chronic stimulation of the right ventricle , the optimal pacing mode should always be considered in these patients at the time of implantation . This study was designed to evaluate the potential benefits of treatment with biventricular device in patients with normal systolic function , indication for pacing and impaired atrio-ventricular conduction, by comparing it with the treatment with dual chamber device

Study Type

Interventional

Enrollment (Anticipated)

164

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Como, Italy, 22100
        • Recruiting
        • Azienda Ospedaliera Sant'Anna
        • Contact:
        • Principal Investigator:
          • Gianluca Botto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with standard indications to stimulation with a high probability of paced beats according to the clinical evaluation of the investigators:
  • First degree AV block (PR ≥ 220 ms) and indication for pacing
  • Paroxysmal AV block second degree (Type I and Type II) associated with long-PR (PR ≥ 220 ms)
  • Patient must be able to attend all required follow-up visits at the study center.
  • LVEF> 35%

Exclusion Criteria :

  • Patient is less than 18 years of age.
  • Patients with a life expectancy less than 12 months
  • Indication for CRT in class I and II
  • Third-degree AV block
  • Patients currently enrolled in other studies / logs
  • Patients who are not able to understand and sign an informed consent
  • State of current or planned pregnancy within 12 months of enrollment
  • Inability to understand and complete the questionnaire QOL

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Right ventricular stimulation
patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
right ventricular stimulation with dual chamber pacemaker
Experimental: Biventricular Stimulation
Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
LVEF
Time Frame: 2 years
LVEF (Left Ventricular Ejection Fraction: such as the assessment of systolic function of the left ventricle)
2 years
LVESV
Time Frame: 2 years
LVESV (Left Ventricular End Systolic Volume: such as the assessment of left ventricular remodeling)
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
echocardiographic left ventricular measures
Time Frame: 2 years

. Structure and cardiac function:

  • Left ventricular End Systolic Diameter, Left ventricular End Diastolic Diameter
  • Left Ventricular End Systolic
2 years
Echocardiographic altrial measures
Time Frame: 2 years
Size of the left atrium (diameter and volume)
2 years
Clinical outcome
Time Frame: 2 years

Clinical benefit:

  • 6 minute walking test
  • quality of life questionnaire
  • New York Heart Association class
  • number and duration of hospitalizations
2 years
Atrial fibrillation (AF)
Time Frame: 2 years

Incidence of AF:

  • incidence of persistent AF
  • burden of FA
  • new onset of AF
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Gianluca Botto, S. Anna Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

December 1, 2016

Study Registration Dates

First Submitted

April 15, 2014

First Submitted That Met QC Criteria

May 26, 2014

First Posted (Estimate)

May 30, 2014

Study Record Updates

Last Update Posted (Estimate)

April 21, 2016

Last Update Submitted That Met QC Criteria

April 20, 2016

Last Verified

April 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on First Degree Atrioventricular Block

Clinical Trials on Dual chamber pacemaker

3
Subscribe